Overview

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)

Status:
Not yet recruiting
Trial end date:
2025-01-06
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with CRSwNP.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline